Skip to Content
Merck
CN
  • Preclinical and clinical evaluation of O-[11C]methyl-L-tyrosine for tumor imaging by positron emission tomography.

Preclinical and clinical evaluation of O-[11C]methyl-L-tyrosine for tumor imaging by positron emission tomography.

Nuclear medicine and biology (2005-04-12)
Kiichi Ishiwata, Hideo Tsukada, Kazuo Kubota, Tadashi Nariai, Norihiro Harada, Kazunori Kawamura, Yuichi Kimura, Keiichi Oda, Ren Iwata, Kenji Ishii
ABSTRACT

We performed preclinical and clinical studies of O-[11C]methyl-L-tyrosine, a potential tracer for imaging amino acid transport of tumors by positron emission tomography (PET). Examinations of the radiation-absorbed dose by O-[11C]methyl-L-tyrosine and the acute toxicity and mutagenicity of O-methyl-L-tyrosine showed suitability of the tracer for clinical use. The whole-body imaging of monkeys and healthy humans by PET showed low uptake of O-[11C]methyl-L-tyrosine in all normal organs except for the urinary track and bladder, suggesting that the O-[11C]methyl-L-tyrosine PET has the potential for tumor imaging in the whole-body. Finally, the brain tumor imaging was preliminarily demonstrated.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
L-Tyrosine, BioUltra, ≥99.0% (NT)
Sigma-Aldrich
L-Tyrosine, FG
Sigma-Aldrich
L-Tyrosine, from non-animal source, meets EP, USP testing specifications, suitable for cell culture, 99.0-101.0%
SAFC
L-Tyrosine
Sigma-Aldrich
L-Tyrosine, reagent grade, ≥98% (HPLC)
Supelco
L-Tyrosine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
L-Tyrosine, Pharmaceutical Secondary Standard; Certified Reference Material